Skip to main content
Fig. 4 | Molecular Cancer

Fig. 4

From: Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison

Fig. 4

Efficacy, adverse events, and survival outcome of bispecific antibody treatment and ICI combination therapies in patients with Digestive system tumors. a A histogram depicting the antitumor activity of BSABs and ICIs combination therapies in in patients with digestive system tumors. EC, esophageal cancer; HCC, hepatocellular carcinoma; BTC, biliary tract cancer; CRC, colorectal cancer; AK104, Cadonilimab; MCLA-128, Zenocutuzumab; ZW25, Zanidatamab. The ORR, defined as a sum of CR and PR. b A forest plot charting the survival outcomes of BSABs and ICIs combination therapies in patients with digestive system tumors. PD-L1 CPS, PD-L1 combined positive score. c A histogram depicting the incidence of grade ≥ 3 TRAEs, as well as major compositions of grade ≥ 3 TRAEs with BSABs and ICIs combination therapies in patients with digestive system tumors. A bar with a value of 0 means not mentioned in the article

Back to article page

Molecular Cancer

ISSN: 1476-4598